Curevo Presents Positive Shingles Vaccine Outcomes Data Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine

Curevo Vaccine Presents Amezosvatein Shingles Vaccine Data at ID Week Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein elicits robust immune responses with better tolerability.

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved...

Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix -- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including...

Did CDC Suppress Data on Chickenpox Vaccine? Asks Article in Journal of American Physicians and Surgeons TUCSON, Ariz., March 29, 2022 (GLOBE NEWSWIRE) -- The chickenpox (varicella) vaccine has markedly decreased the incidence of chickenpox. Although chickenpox is almost always a mild disease,...